Analysis of Response and Progression Patterns of Tyrosine Kinase Inhibitors in Recurrent or Metastatic Adenoid Cystic Carcinoma: A Post Hoc Analysis of Two KCSG Phase II Trials
- Author:
Youjin KIM
1
;
Bhumsuk KEAM
;
Eun Joo KANG
;
Jin-Soo KIM
;
Hye Ryun KIM
;
Keun-Wook LEE
;
Jung Hye KWON
;
Kyoung Eun LEE
;
Yaewon YANG
;
Yoon Hee CHOI
;
Min Kyoung KIM
;
Jun Ho JI
;
Tak YUN
;
Moon Young CHOI
;
Ki Hyeong LEE
;
Sung-Bae KIM
;
Myung-Ju AHN
Author Information
- Publication Type:Original Article
- From:Cancer Research and Treatment 2024;56(4):1068-1076
- CountryRepublic of Korea
- Language:English
-
Abstract:
Purpose:In this study, we evaluated 66 patients diagnosed with adenoid cystic carcinoma (ACC) enrolled in two Korean Cancer Study Group trials to investigate the response and progression patterns in recurrent and/or metastatic ACC treated with vascular endothelial growth factor receptor tyrosine kinase inhibitors (VEGFR-TKIs).
Materials and Methods:We evaluated 66 patients diagnosed with ACC who were enrolled in the Korean Cancer Study Group trials. The tumor measurements, clinical data, treatment outcomes, and progression patterns of therapy were analyzed.
Results:In the 66 patients (53 receiving axitinib and 13 receiving nintedanib), the disease control rate was 61%, and three patients achieved partial response. The median follow-up, median progression-free survival (PFS), overall survival, and 6-month PFS rate were 27.6%, 12.4%, and 18.1% months and 62.1%, respectively. Among 42 patients who experienced progression, 27 (64.3%) showed target lesion progression. Bone metastasis was an independent poor prognostic factor.
Conclusion:Overall, most patients demonstrated stable disease with prolonged PFS; however, prominent target lesion progression occurred in some patients. Thus, PFS may capture VEGFR-TKI efficacy better than the objective response rate.
